MSN 621 FINAL EXAM 3 2026 COMPLETE ANSWERS PATIENT CARE MANAGEMENT PRACTICE RESOURCE

MSN 621 FINAL EXAM 3 2026 COMPLETE
ANSWERS PATIENT CARE MANAGEMENT
PRACTICE RESOURCE

◉ How can antipsychotics cause breast discharge.
Answer: · By blocking the tuberoinfundibular pathway (projects
from hypothalamus to pituitary gland), which is normally tonically
active and inhibits prolactin release
· This blockade causes a rise in prolactin--> galactorrhea


◉ Metabolic monitoring/labs for antipsychotics.
Answer: · Weight/BMI
· Fasting triglycerides
· Fasting glucose
· BP
Liver fnt


◉ Treatments approved for bipolar depression.
Answer: · Lamotrigine- approved to prevent recurrence of
depression, not treatment
· Quetiapine
· Lurasidone

,· Olanzapine + fluoxetine
· Cariprazine


◉ Approved augmenting agents for SSRIs/SNRIs in unipolar
depression.
Answer: · Buproprion
o Olanzapine-fluoxetine
o Quetiapine
o Aripiprazole
o Brexpiprazole
o Ketamine
o Lithium
o Buspirone
o Mirtazapine


◉ Buproprion as augmenting agent for unipolar depression.
Answer: · weak NET and DAT inhib, decreases sexual dysfunction
and improves the symptoms associated with "reduced positive
affect" (loss of happiness, joy, interest, pleasure, energy etc.)


◉ Olanzapine as augmenting agent for unipolar depression.
Answer: Olanzapine-fluoxetine: olanzapine as a D2/5HT2A/5HT2C
antagonists--> actions most likely due to SERT/5HT2C antagonism

, Weight gain/metabolic disturbances SE


◉ Quetiapine as augmenting agent for unipolar depression.
Answer: 5HT2C/NET/5HT1A antagonism actions


Sedation, weight gain, and metabolic disturbances SE


◉ Aripiprazole as augmenting agent for unipolar depression.
Answer: D2/5HT1A partial agonist




Akathisia SE


◉ Brexpiprazole as augmenting agent for unipolar depression.
Answer: D2/5HT1A partial agonist


Decreased akathisia risk


◉ Ketamine as augmenting agent for unipolar depression.
Answer: NMDA antagonist